ASC10

DRUG2 trials

Sponsors

Ascletis Pharmaceuticals Co., Ltd.

Conditions

SARS CoV 2 Infection

Phase 1

Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects

CompletedNCT05523141

Ascletis Pharmaceuticals Co., Ltd.SARS CoV 2 Infection

Start: 2022-10-07End: 2022-12-05Updated: 2022-12-16

Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients

WithdrawnNCT05596045

Ascletis Pharmaceuticals Co., Ltd.SARS CoV 2 Infection

Start: 2022-11-28End: 2023-10-09Updated: 2024-11-01

Related Papers

Safety, tolerability and pharmacokinetics of ASC10, a novel oral double prodrug of a broad-spectrum antiviral agent, β-d-N4-hydroxycytidine: results from a randomized, double-blind, placebo-controlled phase 1 study in Chinese healthy subjects

Expert Opinion on Investigational Drugs2024-07-114 citations